Premium
Lung ultrasound in the diagnosis and monitoring of 30 children with coronavirus disease 2019
Author(s) -
Musolino Anna Maria,
Supino Maria Chiara,
Buonsenso Danilo,
Papa Raffaele Edo,
Chiurchiù Sara,
Magistrelli Andrea,
Barbieri Maria Antonietta,
Raponi Massimiliano,
D'Argenio Patrizia,
Villani Alberto,
Tomà Paolo
Publication year - 2021
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25255
Subject(s) - medicine , lung ultrasound , covid-19 , lung disease , lung , disease , ultrasound , emergency department , pandemic , respiratory disease , coronavirus , abnormality , pediatrics , emergency medicine , radiology , infectious disease (medical specialty) , psychiatry
Background The coronavirus disease 2019 (COVID‐19) has caused a new global pandemic and is responsible for millions of infections and thousands of deaths in the world. The lung ultrasound (LUS) is a noninvasive and easily repeatable tool and can be carried out by the pediatrician at the bedside of children with a consequent reduction in the risk of transmission of the virus. Objective We hypothesized that ultrasound findings in these patients would (1) be associated with their disease severity and (2) change over time in alignment with clinical outcome. Methods The study was made in the emergency department (ED) in a tertiary level pediatric hospital. All patients with swab‐confirmed COVID‐19 infection were subjected to a LUS within 6 h from admission and after 96 h. Results Among a total of 30 children, 18 (60%) were males, 4 reported exertional dyspnea, and only 1 chest pain. The mean oxygen saturation was 98.8 ± 1.0% in ambient air in the ED and no patient needed oxygen therapy during hospitalization. Children with moderate disease presented more B line ( p = .03). After 96 h, we had observed ultrasound abnormality only in 20% of the children. We found a statistically significant reduction in pleural irregularities (30% vs. 16.7; p = .001) and in B lines (50% vs. 20%; p = .008). Conclusions The LUS is a useful, feasible, and safe tool for the clinician to complement the clinical evaluation and to monitor the evolution of lung disease in children with COVID‐19.